Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
02. August 2022 07:30 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced the first patient has been dosed in the pivotal LADDER trial (A Phase 3,...
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
01. August 2022 07:00 ET
|
Avalo Therapeutics
Avalo to receive an approximately $15 million upfront payment, up to $74 million in milestone payments.Apollo to lead continued clinical development of AVTX-007, currently in Phase 1b ROCKVILLE, Md....
Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split
06. Juli 2022 16:05 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., July 06, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a one-for-twelve reverse stock split of the Company’s common stock, par value...
Avalo to Present at the 2022 Jefferies Healthcare Conference
02. Juni 2022 07:30 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present...
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)
18. Mai 2022 07:30 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced that the first patient has been dosed in the company’s Phase 2 PEAK (A Phase 2,...
Avalo to Present at the H.C. Wainwright Global Life Sciences Conference
17. Mai 2022 07:30 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., May 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present...
Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates
05. Mai 2022 07:30 ET
|
Avalo Therapeutics
Reaffirms milestone timing for Phase 2 clinical trial of AVTX-002 in non-eosinophilic asthma (NEA) and pivotal trial of AVTX-803 in leukocyte adhesion deficiency type II (LAD II)Executed workforce...
Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference
08. März 2022 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and...
Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates
02. März 2022 07:30 ET
|
Avalo Therapeutics
Dr. Garry Neil and Chris Sullivan promoted to Chief Executive Officer and Chief Financial Officer, respectivelyAnnounced plans to initiate a Phase 2 randomized, double-blind, placebo-controlled trial...
Avalo Therapeutics Announces Leadership Transition
17. Februar 2022 07:30 ET
|
Avalo Therapeutics
Promotes Dr. Garry Neil to Chief Executive OfficerPromotes Chris Sullivan to Chief Financial Officer WAYNE, Pa. and ROCKVILLE, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc....